Hettenbach, A.; Elger, T.; Huss, M.; Liebisch, G.; Höring, M.; Loibl, J.; Kandulski, A.; Müller, M.; Tews, H.C.; Buechler, C.
Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease. Pathophysiology 2025, 32, 13.
https://doi.org/10.3390/pathophysiology32020013
AMA Style
Hettenbach A, Elger T, Huss M, Liebisch G, Höring M, Loibl J, Kandulski A, Müller M, Tews HC, Buechler C.
Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease. Pathophysiology. 2025; 32(2):13.
https://doi.org/10.3390/pathophysiology32020013
Chicago/Turabian Style
Hettenbach, Angelika, Tanja Elger, Muriel Huss, Gerhard Liebisch, Marcus Höring, Johanna Loibl, Arne Kandulski, Martina Müller, Hauke Christian Tews, and Christa Buechler.
2025. "Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease" Pathophysiology 32, no. 2: 13.
https://doi.org/10.3390/pathophysiology32020013
APA Style
Hettenbach, A., Elger, T., Huss, M., Liebisch, G., Höring, M., Loibl, J., Kandulski, A., Müller, M., Tews, H. C., & Buechler, C.
(2025). Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease. Pathophysiology, 32(2), 13.
https://doi.org/10.3390/pathophysiology32020013
